Sellas Life Sciences Group Inc (SLS)

Currency in USD
4.910
+0.050(+1.03%)
Closed·
4.9100.000(0.00%)
·
SLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.8204.950
52 wk Range
1.2606.140
Key Statistics
Prev. Close
4.86
Open
4.9
Day's Range
4.82-4.95
52 wk Range
1.26-6.14
Volume
2.63M
Average Vol. (3m)
6.59M
1-Year Change
283.5938%
Book Value / Share
0.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.667
Upside
+76.51%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Compare SLS to Peers and Sector

Metrics to compare
SLS
Peers
Sector
Relationship
P/E Ratio
−32.8x−3.4x−0.5x
PEG Ratio
−0.63−0.090.00
Price / Book
12.4x5.9x2.6x
Price / LTM Sales
-64.2x3.2x
Upside (Analyst Target)
105.8%179.7%47.6%
Fair Value Upside
Unlock3.0%6.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.667
(+76.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy7.00+42.57%4.00MaintainJul 15, 2025

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
-0.05 / -0.07
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SLS Income Statement

People Also Watch

7.78
IBRX
+2.37%
3.30
BATL
-1.49%
4.8900
SIDU
-7.91%
1.230
RXT
-0.81%
142.520
AAOI
-2.64%

FAQ

What Is the Sellas Life Sciences (SLS) Stock Price Today?

The Sellas Life Sciences stock price today is 4.910 USD.

What Stock Exchange Does Sellas Life Sciences Trade On?

Sellas Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Sellas Life Sciences?

The stock symbol for Sellas Life Sciences is "SLS."

What Is the Sellas Life Sciences Market Cap?

As of today, Sellas Life Sciences market cap is 887.140M USD.

What Is Sellas Life Sciences's Earnings Per Share (TTM)?

The Sellas Life Sciences EPS (TTM) is -0.246.

When Is the Next Sellas Life Sciences Earnings Date?

Sellas Life Sciences will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is SLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sellas Life Sciences Stock Split?

Sellas Life Sciences has split 3 times.

How Many Employees Does Sellas Life Sciences Have?

Sellas Life Sciences has 13 employees.

What is the current trading status of Sellas Life Sciences (SLS)?

As of Apr 16, 2026, Sellas Life Sciences (SLS) is trading at a price of 4.910 USD, with a previous close of 4.860 USD. The stock has fluctuated within a day range of 4.820 USD to 4.950 USD, while its 52-week range spans from 1.260 USD to 6.140 USD.

What Is Sellas Life Sciences (SLS) Price Target According to Analysts?

The average 12-month price target for Sellas Life Sciences is 8.667 USD, with a high estimate of 10 USD and a low estimate of 6 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +76.51% Upside potential.

What Is the SLS Premarket Price?

SLS's last pre-market stock price is 4.900 USD. The pre-market share volume is 61,180.000, and the stock has decreased by 0.040, or 0.820%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.